CD4 and alopecia: The authors found a higher proportion of patients achieving SRI-6 response and SRI-8 response compared with patients treated with placebo, and more patients had clinical remission, such as resolved arthritis, rash, mucosal ulcers, alopecia, and increased percentage of CD3+CD4+Foxp3+CD127loCD25hi Treg cells and CD3-CD56+ NK cells (158).